LOUISVILLE, Colo., May 15 /PRNewswire/ -- GlobeImmune, Inc. today announced that Jeffrey Rona has joined as Chief Business Officer. "Jeff's extensive experience will add significantly to the senior management team and help us continue to grow the company," said Dr. Timothy C. Rodell, CEO of GlobeImmune, "I am delighted that we have been able to attract someone of Jeff's caliber and integrity to GlobeImmune."
Mr. Rona brings over 15-years experience in originating, structuring and executing corporate transactions and financings. Most recently, Mr. Rona was Vice President of Corporate Development for Corgentech, Inc. following the merger between Corgentech and AlgoRx Pharmaceuticals in late 2005. Prior to the merger, Mr. Rona was the Chief Financial Officer of AlgoRx, and was responsible for the execution of the merger with Corgentech. Mr. Rona also led AlgoRx $65 million Series C financing in early 2004. Prior to joining AlgoRx in 2002, Mr. Rona was in the Investment Banking department at UBS Warburg. Mr. Rona has also served as the director of finance and corporate development at Antigenics, taking the Company public in early 2000. Mr. Rona started his career at Coopers & Lybrand where he spent seven years serving clients needs in accounting, tax and corporate finance. Mr. Rona received a B.S. in Accounting from Case Western Reserve University in 1990.
About GlobeImmune, Inc.
GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapy products called Tarmogens(TM) for the treatment of cancer and infectious diseases. The Company's lead product series, GI-4000 for the treatment of cancers of the lung and gastrointestinal tract, has completed a Phase 1 clinical trial. The Company has an ongoing Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection.
Tarmogens are whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express one or more protein antigens that stimulate the immune system to eliminate diseased cells. Tarmogens are avidly taken up by the cells that activate the immune system called antigen presenting cells, to stimulate a "killer T cell" response against the desired target(s). GlobeImmune's patented Tarmogen platform has a number of advantages over current approaches including that Tarmogens generate potent T cell immune responses, are not neutralized by the immune system, can be rapidly engineered and are simple to manufacture.
For additional information, please visit the company's website at www.globeimmune.com.
This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions investors not to place undue reliance on the forward-looking statements contained in this release.
GlobeImmune, Inc.CONTACT: Timothy C. Rodell, M.D., Chief Executive Officer of GlobeImmune,Inc., +1-303-625-2700, or fax, +1-303-625-2710, information@globeimmune.com
Web site: http://www.globeimmune.com/
